VYNE Therapeutics
VYNE
23 hedge funds and large institutions have $1.1M invested in VYNE Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 15 reducing their positions, and 19 closing their positions.
10.31% more ownership
Funds ownership: 0.7% → 11.01% (+10%)
0% more capital invested
Capital invested by funds: $1.1M → $1.1M (+$3.63K)
44% less funds holding
Funds holding: 41 → 23 (-18)
60% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 15
95% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DA
DSC Advisors
Chicago,
Illinois
|
+$99.7K |
| 2 |
SCA
STALEY CAPITAL ADVISERS
Pittsburgh,
Pennsylvania
|
+$71.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$61.4K |
| 4 |
HF
HRT Financial
New York
|
+$37K |
| 5 |
Millennium Management
New York
|
+$718 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$193K |
| 2 |
Renaissance Technologies
New York
|
-$81.1K |
| 3 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$20.2K |
| 4 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$17.3K |
| 5 |
Franklin Resources
San Mateo,
California
|
-$14.4K |
VYNE Hedge Fund Activity: Q1 2023 in Review
23 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2023, worth a combined $1.1M — up 0.33% from $1.1M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of VYNE and 1 opened new positions — a net loss of 18 holders — while 15 trimmed existing stakes and 6 added.
The largest buyer was DSC Advisors, adding an estimated $99.7K. The largest seller was Vanguard Group, cutting an estimated $193K.
- 23 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2023, down from 41 in Q4 2022.
- Funds reported $1.1M of VYNE Therapeutics stock for Q1 2023, up 0.33% quarter-over-quarter.
- 1 fund opened new VYNE Therapeutics positions in Q1 2023 and 19 closed out, a net change of -18 holders.
- The largest VYNE Therapeutics buyer in Q1 2023 was DSC Advisors, an estimated $99.7K added.
- The largest VYNE Therapeutics seller in Q1 2023 was Vanguard Group, an estimated $193K sold.
Based on aggregated 13F filings for Q1 2023.